The caspase-3 inhibitor (peptide Z-DEVD-FMK) affects the survival and function of platelets in platelet concentrate during storage.
- Author:
Reza SHIRI
1
;
Fatemeh YARI
;
Minoo AHMADINEJAD
;
Shahram VAELI
;
Mohammad Reza TABATABAEI
Author Information
- Publication Type:Original Article
- Keywords: Platelet concentrate; Storage; Caspase inhibitor; von Willebrand factor
- MeSH: Apoptosis; Arachidonic Acid; Blood Platelets*; Blood Transfusion; Caspase 3*; Cell Survival; Incubators; Plastics; Platelet Aggregation; Ristocetin; von Willebrand Factor
- From:Blood Research 2014;49(1):49-53
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND: Although apoptosis occurs in nucleated cells, studies show that this event also occurs in some anucleated cells such as platelets. During storage of platelets, the viability of platelets decreased, storage lesions were observed, and cells underwent apoptosis. We investigated the effects of caspase-3 inhibitor on the survival and function of platelets after different periods of storage. METHODS: Platelet concentrates were obtained from the Iranian Blood Transfusion Organization in plastic blood bags. Caspase-3 inhibitor (Z-DEVD-FMK) was added to the bags. These bags along with control bags to which no inhibitor was added were stored in a shaking incubator at 22degrees C for 7 days. The effects of Z-DEVD-FMK on the functionality of platelets were analyzed by assessing their ability to bind to von Willebrand factor (vWF) and to aggregate in the presence of arachidonic acid and ristocetin. Cell survival was surveyed by MTT assay. RESULTS: At day 4 of storage, ristocetin-induced platelet aggregation was significantly higher in the inhibitor-treated (test) than in control samples; the difference was not significant at day 7. There was no significant difference in arachidonic acid-induced platelet aggregation between test and control samples. However, at day 7 of storage, the binding of platelets to vWF was significantly higher in test than in control samples. The MTT assay revealed significantly higher viability in test than in control samples at both days of study. CONCLUSION: Treatment of platelets with caspase-3 inhibitor could increase their functionality and survival.
